Introduction

Patient details
93
Plasma samples were isolated from blood of ten tolerant patients with cystic fibrosis prior to 94 piperacillin exposure and immediately after a standard 14 day treatment course (4.5g qds) and 95 three piperacillin hypersensitive patients at the time the reaction was diagnosed. Clinical 96 characteristics of the patients are summarized in Table 1 . Plasma was aliquoted stored at - modified peptides with a missed cleavage at the modified lysine residue were used together each sample was normalised to an internal synthetic peptide ATKEQLK that contains 166 unmodified K541: in this way, the MRM signals were adjusted for differences in sample 167 loading on-column. Relative quantification of modified peptides was performed by 168 comparing the relative normalized MRM peak areas for each of the modified residues across 169 samples. To achieve the absolute quantity of piperacillin modification formed in vitro, in cell 170 culture medium, and in patients, synthetic piperacillin-modified peptide ATK(Pip)EQLK was 171 spiked into tryptic HSA digests to construct calibration curves. Six calibration standards 172 containing peptide ATK(pip)EQLK (30, 75, 150, 225, 375, 750 fmol) were prepared. The 173 quantities of piperacillin modification in samples were calculated against calibration curve.
175
Synthesis of drug-modified albumin conjugates
176
Synthetic drug HSA conjugates were generated for functional studies by incubating drugs 177 (piperacillin, penicillin G, and amoxicillin) with HSA at molar ratio of 2:1-250:1 for 24 h in 178 phosphate buffer. The conjugates were purified by ultracentrifuge with a 3,000 MW cut off 179 centrifugal filter (Amicon Ultra-15, Millipore, UK) according to the manufactory's protocol.
180
Briefly, 600 µL conjugates were added to the filter device followed by addition of 14 mL 181 phosphate buffer (10mM, pH7.4). The device was centrifuged at 5000Xg for 20 min and the cloned by serial dilution using established methodology without purification of CD4+ or was performed using paired T test (Sigmaplot 12 software).
Results
237
Synthesis of piperacillin-modified albumin peptides
238
To quantify drug hapten albumin binding a piperacillin-modified HSA peptide incorporating prevented the piperacillin-specific activation of all clones (results not shown).
296
In contrast to our previous study using a piperacillin-albumin conjugate purified through 297 solvent precipitation (free piperacillin concentration, 150nM) (7), clones were not activated 298 with the albumin conjugate used herein ( Figure 3G ). As described above, free piperacillin 299 was removed from the conjugate by repeated ultrafiltration and the non-covalently bound 300 drug concentration was less than 2.5nM.
302
The level of piperacillin hapten adduct required for triggering T-cells was determined by to activate the clones and the kinetics for T-cell activation (i.e., the antigen presenting cell 341 pulse duration) were the same as described with clones depicted in figures 3 and 4.
343
The synthetic piperacillin-HSA conjugates were characterised by mass spectrometry and 344 western blot. Epitope profiling showed that both cyclised and hydrolysed hapten were was also mirrored using western blotting ( Figure 5K ). proliferate and secrete effector molecules, including the tissue-specific cytokine IL-22 (7,22).
376
El-Ghaiesh et al (7) found that all piperacillin-responsive clones were activated with a 377 piperacillin HSA adduct containing 150nM piperacillin bound non-covalently to the protein.
378
We repeated these experiments and found comparable results (data not shown). However, in 379 the present study using a fully characterised, and highly purified HSA adduct, for which we 380 have used low molecular weight mass spectrometry to exclude the presence of non-381 covalently-associated piperacillin above an analytical limit of 2. formed in all patients exposed to the drug.
399
The availability of piperacillin hapten-specific clones with specificity for albumin adducts 400 lead us to investigate whether the level of piperacillin HSA modification differs in tolerant 401 and hypersensitive individuals exposed to the same treatment regimen. To do this, a synthetic 402 drug hapten peptide standard incorporating amino acid residues found in the native protein
403
(38,39) was generated. 3.9% of Lys 541 in HSA isolated from plasma of tolerant patients amoxicillin, or piperacillin-modified HSA (generated using a molar ratio of (C) 100:1 or (D) 
